UroGen Pharma develops and commercializes non-surgical treatments for urothelial cancers, built around its proprietary RTGel reverse-thermal hydrogel that keeps drugs in contact with the urinary tract longer. Its approved product Jelmyto (mitomycin gel) is used for low-grade upper tract urothelial cancer in adults, a niche where kidney-sparing options matter. The company also advances related intravesical candidates such as UGN-102 for low-grade non-muscle invasive bladder cancer, targeting urologists and oncology specialists.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 24.2 | — | -49.9 | — |
| Q3 2025 | 27.5 | — | -33.4 | — |
| Q4 2025 | 37.8 | — | -26.4 | — |
| Q1 2026 | 51 | — | -23.6 | — |
| Q2 2026 | 72.5 | 199.2% | -14.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: ADMA Biologics, Inc. (ADMA), Zymeworks Inc. (ZYME), Perdoceo Education Corporation (PRDO), Allegiant Travel Company (ALGT), Polibeli Group Ltd (PLBL), Establishment Labs Holdings Inc. (ESTA)